文献速递核素与放射性配体治疗肿瘤 PET/CT

[177Lu]-PSMA-I&T 放射性配体治疗在80岁以上转移性去势抵抗性前列腺癌患者中的安全性与疗效:80例80岁以上患者报告

Safety and Efficacy of [177Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years.
PubMed 文献 · J Nucl Med · 2023-06-15

回顾性分析80例≥80岁转移性去势抵抗性前列腺癌(mCRPC)患者接受[177Lu]-PSMA-I&T放射性配体治疗,中位4个周期、中位累积活度23.8 GBq,37例(46.3%)患者PSA下降≥50%,中位临床无进展生存期(cPFS)8.7个月、总生存期(OS)16.1个月;未化疗患者PSA缓解率及cPFS、OS均优于化疗后患者;3级毒性以贫血4例(5%)、血小板减少3例(3.8%)、肾功能损害4例(5%)为主,无4级毒性。

要点

  • ≥80岁mCRPC患者接受[177Lu]-PSMA-I&T治疗,37例(46.3%)PSA下降≥50%,中位cPFS 8.7个月、OS 16.1个月。
  • 未化疗患者50%PSA缓解率51.0%高于化疗后患者38.7%,中位cPFS 10.5 vs 6.5个月、OS 20.7 vs 11.8个月(P<0.05)。
  • 3级毒性为贫血4例(5%)、血小板减少3例(3.8%)、肾功能损害4例(5%),无4级毒性。

核心结论

  • [177Lu]-PSMA-I&T RLT在≥80岁mCRPC患者中安全有效,与既往非年龄选择队列数据相当,高级别毒性发生率低。
  • 未化疗患者对治疗的应答更好且更持久,优于紫杉烷类预处理患者。
  • [177Lu]-PSMA RLT似乎对老年患者是一种有意义的治疗选择。

研究设计与样本

  • 回顾性选取80例≥80岁mCRPC患者,接受[177Lu]-PSMA-I&T RLT。
  • 患者既往接受过雄激素受体靶向治疗、紫杉烷类化疗或不符合化疗条件。
  • 计算最佳PSA应答、临床无进展生存期(cPFS)和总生存期(OS),毒性数据采集至末次治疗周期后6个月。

主要发现

  • 80例中49例(61.3%)未接受过化疗,16例(20%)有内脏转移,既往mCRPC治疗方案中位数为2。
  • 共324个周期(中位4个周期,范围1-12),中位累积活度23.8 GBq(四分位距14.8-42.2)。
  • 37例(46.3%)患者实现PSA下降50%;未化疗患者50%PSA缓解率51.0% vs 化疗后患者38.7%。
  • 总体中位cPFS 8.7个月、OS 16.1个月;未化疗患者中位cPFS 10.5 vs 6.5个月、OS 20.7 vs 11.8个月(P<0.05)。
  • 基线血红蛋白较低和乳酸脱氢酶较高是cPFS和OS较短的独立预测因素。

关键数值与推荐

  • 3级治疗中出现毒性:贫血4例(5%)、血小板减少3例(3.8%)、肾功能损害4例(5%)。
  • 未观察到非血液学3级毒性和4级毒性。
  • 最常见临床副作用为1-2级口干、乏力和食欲不振。

临床怎么用

  • 原文结论认为[177Lu]-PSMA-I&T RLT在≥80岁mCRPC患者中安全有效,高级别毒性发生率低。
  • 原文结论认为未化疗患者应答更好且更持久,优于紫杉烷类预处理患者。
  • 原文结论认为[177Lu]-PSMA RLT似乎对老年患者是一种有意义的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

177Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a new treatment option for metastatic castration-resistant prostate cancer (mCRPC). Its low toxicity profile favors use in elderly patients or in patients with critical comorbidities. The purpose of this analysis was to evaluate the efficacy and safety of [177Lu]-PSMA RLT in mCRPC patients at least 80 y old. Methods: Eighty mCRPC patients at least 80 y old underwent [177Lu]-PSMA-I&T RLT and were retrospectively selected. The patients were previously treated by androgen receptor-directed therapy, received taxane-based chemotherapy, or were chemotherapy-ineligible. The best prostate-specific antigen (PSA) response was calculated, as well as clinical progression-free survival (cPFS) and overall survival (OS). Toxicity data were acquired until 6 mo after the last treatment cycle. Results: Of 80 patients, 49 (61.3%) were chemotherapy-naïve and 16 (20%) had visceral metastases. The median number of previous mCRPC treatment regimens was 2. In total, 324 cycles (median, 4 cycles; range, 1-12) with a median cumulative activity of 23.8 GBq (interquartile range, 14.8-42.2) were applied. A PSA decline of 50% was achieved in 37 (46.3%) patients. Chemotherapy-naïve patients showed higher 50% PSA response rates than chemotherapy-pretreated patients (51.0% vs. 38.7%, respectively). Overall, median cPFS and OS were 8.7 and 16.1 mo, respectively. The median cPFS and OS of chemotherapy-naïve patients were significantly longer than those of chemotherapy-pretreated patients (10.5 vs. 6.5 mo and 20.7 vs. 11.8 mo, respectively, P < 0.05). A lower hemoglobin level and higher lactate dehydrogenase level at baseline were independent predictors of shorter cPFS and OS. Treatment-emergent grade 3 toxicities were anemia in 4 patients (5%), thrombocytopenia in 3 patients (3.8%), and renal impairment in 4 patients (5%). No nonhematologic grade 3 and no grade 4 toxicities were observed. The most frequent clinical side effects were grade 1-2 xerostomia, fatigue, and inappetence. Conclusion: [177Lu]-PSMA-I&T RLT in mCRPC patients at least 80 y old is safe and effective, comparable to previously published data on non-age-selected cohorts with a low rate of high-grade toxicities. Chemotherapy-naïve patients showed a better and longer response to therapy than taxane-pretreated patients. [177Lu]-PSMA RLT seems to be a meaningful treatment option for older patients.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Tauber R, Knorr K, Retz M, et al. Safety and Efficacy of [177Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years. J Nucl Med. 2023. PMID: 37321824. doi:10.2967/jnumed.122.265259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。